A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC with Multiple Intravenous Infusions of Efgartigimod in Patients with Generalized Myasthenia Gravis (ADAPT)

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2021
This article has no abstract
Epistemonikos ID: ff5793df95a33e3781407b645df290fb8324903e
First added on: Apr 11, 2025